{"id":"W3123764157","doi":"10.1200/jco.2021.39.3_suppl.268","title":"Pembrolizumab (pembro) vs placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the randomized, phase III KEYNOTE-240 study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Sorafenib; Interim analysis; Internal medicine; Placebo; Clinical trial; Hepatocellular carcinoma; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001637901,0.0008743023,0.001604032,0.0003047504,0.0002429816,0.000843111,0.0004767676,0.0007197363,0.003179062],"category_scores_gemma":[0.001539277,0.0004498782,0.001496999,0.0004336817,0.0004335271,0.0007829712,0.0004347784,0.002085053,0.0004012002],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006600523,"about_ca_system_score_gemma":0.0007603705,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007367097,"about_ca_topic_score_gemma":0.00220844,"domain_scores_codex":[0.9995534,0.0002368689,0.00003465473,0.00007447739,0.00003264499,0.00006789358],"domain_scores_gemma":[0.9993351,0.0001809232,0.0002208476,0.00003751243,0.00002849085,0.0001970354],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9477763,0.00426569,0.002479425,0.001001023,0.001900676,0.00006476155,0.00006617737,0.0006886718,0.003943466,0.0001001565,0.001327784,0.03638571],"study_design_scores_gemma":[0.8067126,0.1711973,0.01513894,0.0001094311,0.002503253,0.0001524551,0.00005036515,0.0008119095,0.0009850195,0.0002417673,0.002075804,0.00002108666],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.986163,0.007766105,0.0005203212,0.0005140607,0.0002568352,0.001414469,0.00166717,0.00008876781,0.001609325],"genre_scores_gemma":[0.9933202,0.00246674,0.000495361,0.0004647796,0.0001368074,0.0009977763,0.001190465,0.000009093219,0.000918723],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003179062,"threshold_uncertainty_score":0.01063508,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1209749449190507,"score_gpt":0.3799611787441557,"score_spread":0.258986233825105,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}